Doximity, Inc. (NYSE:DOCS) Stock Rated “Hold” by Wall Street Brokerages

Doximity, Inc. (NYSE:DOCS) has been assigned a consensus rating of “Hold” from the twenty-five brokerages that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $30.73.

A number of equities research analysts recently weighed in on the company. Zacks Research raised Doximity from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Citigroup lowered Doximity to an “underperform” rating in a report on Monday, June 29th. Evercore set a $35.00 target price on Doximity in a research note on Tuesday, September 29th. Weiss Ratings raised shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, October 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Doximity in a report on Friday, August 7th.

Doximity Trading Down 0.5%

Shares of Doximity stock opened at $30.81 on Monday. The company’s fifty day simple moving average is $26.75 and its 200-day simple moving average is $23.63. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 24.22 and a beta of 1.22. Doximity has a 1 year low of $17.15 and a 1 year high of $71.37.

Doximity (NYSE:DOCS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million during the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. Doximity’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the company earned $0.36 earnings per share. As a group, research analysts forecast that Doximity will post 0.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Timothy S. Cabral sold 7,500 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $39.11, for a total transaction of $293,325.00. Following the sale, the director owned 3,221 shares in the company, valued at approximately $125,973.31. This represents a 69.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the sale, the chief accounting officer owned 101,432 shares of the company’s stock, valued at approximately $3,111,933.76. This trade represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 19,250 shares of company stock valued at $613,855. 31.80% of the stock is currently owned by company insiders.

Institutional Trading of Doximity

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc raised its position in Doximity by 1,176.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock worth $52,000 after purchasing an additional 1,683 shares during the last quarter. Fortitude Family Office LLC lifted its holdings in Doximity by 31,271.4% during the 3rd quarter. Fortitude Family Office LLC now owns 2,196 shares of the company’s stock worth $62,000 after buying an additional 2,189 shares in the last quarter. Parallel Advisors LLC boosted its position in Doximity by 111.0% in the 1st quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after buying an additional 1,347 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Doximity by 937.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company’s stock valued at $66,000 after buying an additional 2,560 shares during the last quarter. Finally, Leonteq Securities AG boosted its position in Doximity by 65.6% in the 1st quarter. Leonteq Securities AG now owns 2,912 shares of the company’s stock valued at $68,000 after buying an additional 1,154 shares during the last quarter. 87.19% of the stock is owned by institutional investors.

Key Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity extended its 13-year alliance with U.S. News, supporting physician searches, appointment booking and hospital rankings. The partnership could reinforce user engagement and patient-access offerings. Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
• Neutral Sentiment: Doximity will release fiscal 2027 second-quarter results on November 5, giving investors the next major opportunity to assess growth, advertising trends and management’s outlook. Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Doximity and certain individuals, including co-founder and former Chief Strategy Officer Nate Gross. The allegations reportedly concern statements that Doximity could gain market share while older advertising formats were losing ground to programmatic and social-media competitors; the claims have not been established in court.
• Negative Sentiment: Investors who purchased DOCS shares between August 8, 2024 and May 13, 2026 are being reminded that November 16, 2026 is the deadline to seek appointment as lead plaintiff. Repeated announcements from Robbins Geller, SBS Law, Kaplan Fox, Rosen, Pomerantz, Bronstein Gewirtz Grossman and other firms increase the visibility of the legal overhang and could weigh on sentiment. DOCS Investor Alert

Doximity Company Profile

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.